Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07769138

Implementation of Networked Continuous Glucose Monitoring With Telemetry Within the Intensive Care Unit (ICU-TeleCGM)

The aim of this observational study is to assess safety and implementation of continuous glucose monitors within the Intensive Care Unit. The Dexcom G7 is a continuous glucose monitoring system that shows blood glucose values in real-time and includes alarms if the glucose is very low or high.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Type 1 Diabetes Autoimmune Diseases Continuous Glucose Monitoring Diabetes Mellitus Diabetes Mellitus, Type 1 Endocrine System Diseases Glucose Metabolism Disorders Hyperglycemia Hypoglycaemia Hypoglycemia Immune System Diseases Intensive Care (ICU) Metabolic Diseases Nutritional and Metabolic Diseases Type 2 Diabetes Treated With Insulin

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Imperial College Healthcare NHS Trust

London, United Kingdom

About this study

Aim: To assess safety and implementation of networked CGM with ViewsEMR® telemetry within ICU.

The study will be conducted in a two-stage process:

  • Phase 1: A single arm (non-randomised) unmasked feasibility study with adjunctive use of networked CGM using the Dexcom G7 system and ViewsEMR® telemetry. This phase will be conducted at a single site at Imperial College Healthcare NHS Trust (ICHNT).
  • Phase 2: A randomised, parallel-group pilot study with adjunctive use of networked CGM using the Dexcom G7 system and ViewsEMR® telemetry compared to standard of care. This phase will be conducted at three hospitals within the same site: ICHNT (St Mary's Hospital, Charing Cross Hospital and Hammersmith Hospital). The study will be conducted at Imperial College Healthcare NHS Trust in people with hyperglycaemia on admission to ICU requiring insulin.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >18years inclusive
  • Hyperglycaemia requiring insulin therapy (subcutaneous injection or intravenous insulin) during admission on ICU
  • Admission to ICU within 48hours

Exclusion criteria

  • Known significant allergy to tape/ adhesives
  • Imminent death or anticipated length of stay <24hours
  • Women who are pregnant
  • Imminent extracorporeal membrane oxygenation (ECMO)
  • Requirement for therapeutic temperature control (i.e. cooling) post cardiac arrest

Treatment and study plan

Dexcom G7

Device

Continuous glucose monitoring.

ViewsEMR telemetry

Device

ViewsEMR Telemetry is a digital platform used to monitor participants' real-time CGM data and glucose trends

Primary outcomes

  1. Phase 1: Eligible participants that consent to participate.

    Time frame: Throughout Phase 1 study period, up to 6 months

    Percentage of eligible participants that consent to participate, including the percentage enrolled through participant informed consent, via personal consultee, and via nominated consultee.

  2. Phase 1: Time from admission to ICU to initiation of CGM

    Time frame: From admission to ICU to initiation of CGM, up to 48 hours

    Time in minutes from admission to ICU to initiation of CGM

  3. Phase 1: Time from consent to initiation of CGM

    Time frame: From enrollment to the end of intervention at 10 days

    Time from consent to initiation of CGM

  4. Phase 1: Percentage of CGM data availability for each participant

    Time frame: From enrollment to the end of intervention at 10 days

    Percentage of CGM data availability for each participant

  5. Phase 1: Percentage of participants successfully set-up on telemetry (ViewsEMR ®)

    Time frame: From enrollment to the end of intervention at 10 days

    Percentage of participants successfully set-up on telemetry (ViewsEMR ®)

  6. Phase 1: Number of premature sensor failures per participant (defined as <70% of anticipated use)

    Time frame: From enrollment to the end of intervention at 10 days

    Number of premature sensor failures per participant (defined as <70% of anticipated use)

  7. Phase 1: Number and type of adverse events related to CGM use (e.g., skin irritation, device malfunction)

    Time frame: From enrollment to the end of intervention at 10 days

    Number and type of adverse events related to CGM use (e.g., skin irritation, device malfunction)

  8. Phase 1: Proportion of participants completing the study

    Time frame: Throughout Phase 1 study period, up to 6 months

    Proportion of participants completing the study

  9. Phase 1: Proportion of nursing staff completing study survey

    Time frame: Throughout Phase 1 study period, up to 6 months

    Proportion of nursing staff completing study survey

  10. Phase 2: Number of episodes of hypoglycaemia per participant

    Time frame: Throughout Phase 2, up to 30 days

    Number of episodes of hypoglycaemia per participant (defined as <3.9mmol/L for 15minutes)

Secondary outcomes

  1. Phase 1: Safety Outcomes

    Time frame: From enrollment to the end of intervention, up to 10 days

    • Duration of CGM signal loss (units: minutes)

Study contacts

Contact information is provided by the study sponsor or research team.

Narvada Jugnee, MSc

CONTACT

[email protected]

020 33133706

Parizad Avari, MBBS, PhD

CONTACT

[email protected]

020 33133706

Sponsors and collaborators

Lead sponsor

Imperial College Healthcare NHS Trust

Other

Registry information

Acronym: ICU-TeleCGM

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Aug 17, 2026
Registry last updated
Aug 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.